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Abstract
While testing regenerative medicine strategies, the use of animal models that match the research questions and that are
related to clinical translation is crucial. During the initial stage of evaluating new strategies for bone repair, the main goal is
to state whether the strategies efficiently induce the formation of new bone tissue at an orthotopic site. Here, we present a
subperiosteal model in rat calvaria that allow the evaluation of a broad range of approaches including bone augmentation,
replacement and regeneration. The model is a fast to perform, minimally invasive, and has clearly defined control groups.
The procedure enables to evaluate the outcomes quantitatively using micro-computed tomography and qualitatively by
histology and immunohistochemistry. We established this new model, using bone morphogenetic protein-2 as an
osteoinductive factor and hyaluronic acid hydrogel as injectable biomaterial. We showed that this subperiosteal cranial
model offers a minimally invasive and promising solution for a rapid initial evaluation of injectables for bone repair. We
believe that this approach could be a powerful platform for orthopedic research and regenerative medicine.
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Introduction
Non-union fractures and traumatic bone defects represent
severe medical and socio-economic problems. Currently, the gold
standard for the treatment of such bone defects is the implantation
of autologous bone grafts harvested from the patient’s iliac crest
[1]. While effective, this method is associated with donor site
morbidity and limitations in the amount of bone that can be used
[1,2]. Therefore, an overarching aim in orthopedics is the
development of alternative regenerative medicine therapies that
lead to bone augmentation.
Standards for the biological evaluation of new treatment
modalities, established by the International Organization for
Standardization (ISO) 10993, include the evaluation of a number
of variables that must be evaluated before a product can be
considered safe and efficient for human use. At the moment, the
development of regenerative medicine strategies for bone tissue
from concept to product takes 4–10 years from concept to product
and involves a cost of 5–300 million dollars, depending on the
regulatory process required [3]. As part of this development
process, an evaluation of the approach’s safety and biocompati-
bility and the associated immunological response, as well as its
ability to induce bone formation, can only be achieved in vitro [4]
and in animal models [5,6].
As yet, there is no rapid and simple preclinical model to allow
the evaluation of regenerative strategies for bone. The use of large
animals such as sheep is usually required before clinical trials, since
these animals display characteristics of bone anatomy and biology
that are close to those of human [7,8]. However, the cost and time
course of using large animals are not suitable for the screening and
the rapid testing of new strategies. On the other hand, small
animals, and in particularly rats, are easier to handle and more
suitable for initial testing [9]. With rats, outcomes can be
determined after a short period of time, and the variation between
individuals of the same strain, age, gender, and weight is very small
[10]. The handling of the animals is relatively easy and low-cost,
since they are tolerant of surgery [11]. Finally, it is possible to use
advanced functional imaging techniques for rats that are not
available for large animals [4]. For these and other reasons, rats
are currently the most commonly animal used for musculoskeletal
research (45% of animal research) [11].
In our laboratory, we have gained experience with various
animal models, including the ectopic bone formation model
[12,13] and various defect models [14]. As a standard and a first
approach, the ectopic model is often widely used by researchers in
order to evaluate the osteoinductive capacity of cells, morphogens,
and biomaterials [15]. However, while simple and fast, this model
has a drawback in that the formation of bone occurs in an extra-
osseous site. Therefore, the ectopic bone model is not represen-
tative of the clinical needs. The defect models are much more
clinically relevant, although the size of the defect matters, since
defects that are not large enough heal spontaneously [16]. For
example, critical-size defect models at orthotopic sites such as the
tibia are very relevant, but they are complicated and can be
associated with a high failure rate. Moreover, additional stabili-
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zation by heavy fixation devices is often required, and this may
damage surrounding soft tissues and change biomechanical
conditions are often required [3]. A simpler and more relevant
model to illustrate the potential of clinical translation potential is
that of calvarial defects in the rat [3,17]. However, the surgery is
still relatively long and invasive, and it can yield to non-negligible
variability as the result of bleeding. In addition, as in all defect
models, postoperative treatment with painkillers is required for
several days. Thus, when the defect models are used, the long
surgical intervention and the large injury expose animals to an
extremely stressful situation and to postoperative pain that should
be treated with painkillers. However, it is known that both stress
and the use of painkillers can modify the immune response and
strongly influence bone healing [18–20]. In addition, clinical
applications for constructs inducing bone formation are not
limited to repair defects. For instance, one of the main clinical
applications is spinal fusion [15], in which no defects need to be
repaired.
Recently, there has been an interest in using the periosteal space
of the bone as the site for biomaterial testing, since this cellular
membrane covering the bone is rich in progenitor cells and various
cytokines [21,22]. For instance, Eryilmaz et al. obtained bone
formation while implanting demineralized bone matrix (DBM)
[23]. However, this method required an elevation of the periosteal
flaps and their suturing. In contrast, Fujimoto et al. induced bone
in the subperiosteal space by less invasive injections of transform-
ing growth factor-b (TGF-b) [24]. Nevertheless, in this study
multiple injections were required because TGF-b was applied
without a scaffold. In contrast, Stevens et al. used an injectable
biomaterial that was placed under the periosteal of the tibia in
rabbits and triggered bone formation [25]. Another interesting
study engineered cartilage in the same way [26].
Recently, we have presented a model in which a bone-inducing
construct, a hyaluronic acid (HA) hydrogel loaded with bone
morphogenetic protein-2 (BMP-2), was tested in the periosteal
space of the mandible [6]. The benefit of using HA hydrogel as a
scaffold for BMP-2 is that it becomes a solid mass after mixing.
Also, implantation by injection makes the intervention shorter and
minimally invasive, and therefore it is easier and less stressful for
the animal. However, we found a periosteal mandibular model to
be specifically relevant for alveolar bone augmentation. Therefore,
we now present a new subperiosteal model in the cranial bone of
the rat. The cranial bone is more accessible than mandible, and
the intervention can be controlled visually. This model allowed us
to rapidly evaluate the osteogenic potential of injectable constructs.
Results
1. Surgical Intervention
HA hydrogels without BMP-2 or containing a high (30 mg) or
low (1 mg) dose of BMP-2 were prepared. The constructs or saline
(sham group) were then injected into the periosteal spaces of rat
cranial bones (Fig. 1 A–F). From anesthesia induction to the skin
closure, the surgical intervention lasted approximately 15 min.
The procedure was easy to perform by one surgeon, and all
constructs were injected at a desired site (Video S1). The
periosteum was only punctured once, and no sutures were
required to close it. No rupture of the periosteum or other
perioperative complications were observed. Postoperative recovery
was uneventful, and the animals resumed normal ambulation
without any sign of pain or distress during the study period. The
wounds healed normally and were covered with hairs. No
abnormal behaviour was noted during the 6-week duration of
the study.
2. Efficacy of New Bone Formation
After 6 weeks, the rats were sacrificed, and the cranial bones
were harvested for further evaluation. The volume of new bone
formed was determined by micro-computed tomography (micro-
CT) (Fig 2 A). Quantitative analysis was performed by comparing
the bone volume of specimens from the rats treated with constructs
to those from animals treated with saline. HA hydrogels that did
not contain BMP-2 (gel alone) showed only a slight bone ingrowth
(18 mm3) (Fig. 2 A and B). In contrast, HA hydrogels with either
the high or low dose of BMP-2 were able to cause significant bone
ingrowth (p,0.05): 139 mm3 and 57 mm3, respectively. No
statistically significant difference was found between the gel alone
and the gel with the low dose of BMP-2. In addition, in order to
determine the degree of correlation between the volume of the
new bone formed and the concentration of BMP-2, we determined
the non-parametric Spearman’s correlation coefficient, and found
a significant correlation between both parameters (p,0.001).
Furthermore, the trabecular number (Fig. 2 C), thickness (Fig. 2 D)
and separation (Fig. 2 E) of bones formed by the gels with BMP-2
were significantly higher than the bone induced by gel alone
(Fig. 2). There was only slight difference in the bone porosity
between three groups (Fig. 2 F).
3. New Bone Morphology
Histological assessment of calvarial bone composition at 6 weeks
post-injection was performed on H&E-stained sections to provide
information about the quality and morphologic characteristics of
the newly formed bone tissue. Representative histological images
from each group are shown in Fig. 3. Calvarias injected with HA
hydrogel with a high dose of BMP-2 showed the largest amount of
bone ingrowth (Fig. 3). Within the new bone formed, we observed
structures resembling trabecular bone with bone marrow spaces.
Woven bone with a weak trabecular structure and large bone
marrow spaces was formed in the groups receiving HA hydrogel
containing the lower dose of BMP-2. In this group, more
ossification appeared in the periphery than in the center of the
new bone. As expected, the group without BMP-2 had a minimal
amount of bone formation. In all groups, there was no histological
sign of the presence of inflammatory cells or fibrous tissue.
Moreover, we did not observe cartilage or residual HA hydrogel at
the injection site (data not shown).
As an indicator of the quality of the new bone formed, we
examined the assembly of collagen fibers using Sirius red staining
and detected the presence of osteoclacin (OC), by immunostaining
(Fig. 4). We found collagen fibers of the highest degree
organization, in the group containing the higher concentration
of BMP-2, when compared to those receiving less (or no) BMP-2.
Furthermore, in all experimental groups, positive signals for OC
were detected, at the sites at which tissue ingrowth was identified.
The deposition of bone matrix in the bone tissues formed by the
gels containing 30 mg of BMP-2 was higher than that in the bone
tissue derived from the gels containing 1 mg or no BMP-2 (Fig. 4).
As a control, we used areas of native calvarial bone which were
positive for OC. The negative control (treated only with secondary
antibody) showed no positive staining (data not shown).
4. Angiogenesis within the New Bone Formed
Blood vessels were visualized by immunofluorescent staining for
CD31 (an endothelial-specific marker; Fig. 5A). We observed that
the marrow spaces of the new bone formed were rich in functional
blood vessels containing erythrocytes (marked by green autofluor-
escence).The density of the blood vessel were also quantified. As
shown in Fig. 5 B, HA hydrogels containing the high dose of BMP-
2 had more (16.468.8) blood vessels, as compared to the gel with
Rat Subperiosteal Cranial Model
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the low dose of BMP-2 (15.867.1) and the gel alone (3.360.8).
Therefore, 30 mg as well as 1 mg of BMP-2 in the hydrogels
significantly increased angiogenesis in new bone when compared
to hydrogel alone.
Discussion
Our growing knowledge about stem cells, morphogens,
biomaterials, and delivery systems suggests an incredible number
Figure 1. Key aspects of the surgical procedure. (A, B) The top of a blunt needle is inserted at an angle of 45u into the periosteal space of the
cranial bone and (C) is pushed forward with an angle of 15–20u onto the bone surface towards the face plane. The length of the needle insertion into
the subperiosteal space is visually controlled. After it reaches 1 cm, the tip is moved (D) to the left and (E) to the right, in order to make space for an
injectable construct. (F) The construct is injected in a volume of 200 mL, forming a small bump.
doi:10.1371/journal.pone.0071683.g001
Rat Subperiosteal Cranial Model
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Figure 2. New bone formation. (A) Representative 3D micro-CT reconstruction of cranial bone treated with (i) gel containing 30 mg of BMP-2, (ii)
gel containing 1 mg of BMP-2, (iii) gel without BMP-2, or saline (control) at 6 weeks post-injection. Scale bar is 1 cm. MicroCT analysis of (B) the
trabecular bone volume (BV/TV [mm3]), (C) trabecular number (TbN [/mm2]), (D) trabecular thickness (TbTh [mm]), (E) trabecular separation (TbSp
[mm]), and (F) trabecular porosity (P [%]). Shown are means 6 SD, n = 3. Comparisons between gel groups and the control group were made by two
tailed Student’s t-test for paired samples (*p,0.05; ***p,0.001).
doi:10.1371/journal.pone.0071683.g002
Figure 3. Morphology of the new bone formed. Representative transversal micro-CT reconstructions and cross-sections stained with H&E of
cranial bone treated with gel containing 30 mg of BMP-2, gel containing 1 mg of BMP-2, gel without BMP-2, or no gel (saline control) at 6 weeks post-
injection. The red square on the micro-CT reconstructions represents the area stained with H&E.
doi:10.1371/journal.pone.0071683.g003
Rat Subperiosteal Cranial Model
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of possible combinations for the development of new treatments
for non-union fractures, traumatic bone defects, and spinal fusion
[20]. In order to evaluate the potential of these new treatments, it
has become critical to be able to test them rapidly with
standardized preclinical models. This need applies especially to
emerging strategies that do not yet have specified applications but
that require initial validation.
The development of a standardized model in rats that is
reproducible and easy to perform would be an important
contribution to tissue engineering and orthopedic research. In
the current study, we present a subperiosteal cranial model in rats
that was developed on the basis of our previous observations and
information in the literature, with the goal of producing a rapid,
easy, and reproducible model. We chose the cranial subperiosteal
region for this model, since it is easily accessible and because the
injection can be visually controlled (Video S1). Because the surgery
is based on a single injection and the whole intervention does not
exceed 15 min, a single operator without surgical experience can
perform the intervention. Moreover, the minimally invasive
surgery involved also decreased risk of postoperative infection,
experimental failure [27], and morbidity/mortality. Thus, the fact
that the surgery is minimally invasive is important to consider in
regards to ethical and cost-effectiveness issues, since with currently
used animal models of the lowest invasiveness such as the rat
Figure 4. Quality of the new bone formed. Representative cross sections of cranial bone treated with gel containing 30 mg of BMP-2, gel
containing 1 mg of BMP-2, gel without BMP-2, or no gel (saline control) at 6 weeks post-injection. The specimens were stained with Sirius red to show
collagen fiber orientation and were also stained for OC (in red). Nuclei are in blue. The green-yellowish color represents organized collagen fibers.
doi:10.1371/journal.pone.0071683.g004
Figure 5. Angiogenesis within the new bone formed. Representative cross sections of cranial bone treated with (i) gel containing 30 mg of
BMP-2, (ii) gel containing 1 mg of BMP-2, (iii) gel without BMP-2, or no gel (saline control) at 6 weeks post-injection. Sections were immunostained for
CD31 (green). Erythrocytes in vessels are shown by green autofluorescence. Nuclei are in blue. (B) The number of blood vessels per 10x field was
quantified. Means 6 SD were calculated from n=3 (3 sections per sample). Comparisons between gel groups and the control group were made by
the two tailed Student’s t-test for paired samples (*p,0.05).
doi:10.1371/journal.pone.0071683.g005
Rat Subperiosteal Cranial Model
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calvarial defect model, the morbidity/mortality variable is about
5–10% [28]. In addition, the cranial location offers the advantage
to preventing self-injuries or injuries by other rats housed in the
same cage [29]. Injection into the periosteal space allows the
maintenance of the construct is situ (Fig. 1F) and prevents its
leakage into the surrounding soft tissues. Moreover, the subperi-
osteal space is particularly relevant for direct study of the influence
of a treatment on mesenchymal stem cells, fibroblasts and other
precursor cells, since the periosteum is a source of progenitor cells
[21,22].
Among the currently known regenerative medicine strategies for
bone, the use of scaffolds loaded with bone BMP-2 is one of the
most promising. Clinically available, BMP-2 is involved in the
recruitment and differentiation of bone progenitor cells at the site
of bone injury, and it triggers new bone formation [30]. Thus, for
the development of our model, we used BMP-2 as an
osteoinductive factor. In order to deliver this growth factor, we
used the well-established HA hydrogel as an injectable biomaterial
standard, because HA scaffolds have been shown to be very
efficient as a BMP-2 delivery carriers for BMP-2 in various animal
models [12,14,31]. For example, we have previously shown that
the encapsulation of BMP-2 in HA hydrogel resulted its sustained
release in vitro for almost a month. This efficient encapsulation was
corroborated by potent in vivo bone formation at an ectopic site in
a rat [12] and calvarial defects in mini-pigs [14]. We decided to
use a 6-week time point, because both ectopic and calvarial defect
models in the rat are usually stopped within at 4 to 8 weeks
[15,32,33]. Thus, we believe that a 6-week time period is ideal for
evaluating the efficacy of various treatments.
Using this cranial subperiosteal model, we found a significant
correlation between the dose of BMP-2 delivered and the amount
of new bone formed. This correlation demonstrated the repro-
ducibility of the model and its potential for use in the evaluation of
the tretament efficacy. The same type of relationship was observed
in a previously published study using a subperiosteal mandibular
model in the rat [6]. Using three animals per group, we found low
standard deviations for the new bone volume formed in each
groups (Fig. 2 B), indicating that the variability of the surgical
intervention was low. Furthermore, we found remarkable more
and thicker trabeculae with smaller trabecular separation in the
bone induced by the gel with high BMP-2 compared to the bone
formed by the gel with los BMP-2 and the gel only (Fig. 2C–E).
This account for the trabecular thickening and reduction of the
trabecular space due to a bone ingrowth.
In addition to the micro-CT evaluation, we used histological
staining to further characterize the new bone tissue formed with
this model, using various histological techniques. First, we assessed
the network of trabecular structure, since it is well accepted that
continuity and connectivity of bone trabeculae are important for
the transmission of functional forces in human body. For example,
in osteoporosis, spontaneous fractures occur when trabeculae in
the long bones are resorbed and display disrupted connectivity
[34]. As expected, animals treated with the highest dose of BMP-2
displayed new bone tissue with a dense network of trabeculae
(Fig. 3). In contrast, the animals treated without BMP-2 or with a
low dose of BMP-2 had less extensive trabeculae. As another
marker that appears at the stage of bone formation, we detected
osteocalcin (OC) within the new bone that was formed. Under all
conditions, we were able to detect OC at the sites at which new
tissue ingrowth was identified. However, the highest signal was
shown in the bone tissues induced by the gels containing 30 mg of
BMP-2 (Fig. 4). Furthermore, as another indication of the quality
of the new bone formed, we examined the assembly of collagen
fibers (Fig. 4). We found collagen fibers of higher organization in
the group containing the highest concentration of BMP-2. Finally,
we addressed the amount of angiogenesis within the newly formed
tissue, since the formation of functional blood vessels plays a
pivotal role in skeletal development and bone fracture repair, and
inadequate vascularization delays bone graft regeneration [35].
We observed that the marrow spaces of the new bone formed were
rich in blood vessels containing erythrocytes (Fig. 5). The higher
density of blood vessels was shown in the ectopic bones induced by
the high BMP-2 compared to the low BMP-2 and the gel alone. In
fact, it was previously reported that BMP-2 does not only
stimulates osteogenesis but also enhances angiogenesis [36].
Importantly, in contrast to a previous ectopic bone study in the
rat, we did not observe any remaining gels in any of the groups
which could be explained by the differences in the local cellular
enzymatic activities in the two locations locations used [37].
As a mechanism for bone formation in our model, we propose
the following: (1) The progenitor cells from the calvarial bone and
from the periosteum migrate toward the BMP-2 gradient in
response to its chemotactic activity [38]. The cells adhere to the
gel and penetrate its outer surface. (2) They start to differentiate
into bone cells and produce organic matrix composed mainly of
collagen fibers and non-collagen proteins such as OC. (3)
Angiogenesis occurs within the newly formed tissue and contrib-
utes to the formation of a bone marrow-like tissue. The vessel
network in the new bone is formed from sprouting capillaries
existing in the periosteal space, which are subsequently expanded
and then mature [39]. (4) The bone-like tissue forms an initial shell
of bone that, with time, transforms into a mineralized bone
extending toward the center of the scaffold and replacing the gel
[40].
The robust bone formation in the animals receiving the high
concentration of BMP-2 could be explained by the rapid initial
release of some of the BMP-2, while the amount trapped in the
scaffold could stimulate later differentiation. In case of the gel with
low-dose of BMP-2 it is likely that most of the protein is released at
early stage. Similar sequences of bone formation have been
observed in an ectopic model after 4 weeks [31] and 8 weeks with
the same HA hydrogel in our previous studies [12]. It is also of
interest to us to investigate whether and how the excess of bone
induced by BMP-2 undergoes remodeling. The excessive bone
growth may affect the external contour of the bone, especially in
the craniofacial area, and may also affect surrounding structures
and organs [14]. Because this model, as an orthotopic model, is
suitable for studying osteoclastic resorption in the vicinity of bone,
we will complement the dose-response study with an evaluation of
the earlier and later time points in a future study.
Like other animal models for bone regeneration, this model has
some inherent disadvantages. Rats have quite distinct bone
anatomy from that of humans, because they do not have a
Harversian system [4]. Therefore, the minimum dose of BMPs
necessary to induce consistent bone formation is higher in humans
than in rodents [41]. However, the models based on the rat offer
the possibility of testing strategies involving non-autologous cells
and even xenogenic cells, because athymic rats are available [42].
Another limitation is that this model is not based on a defect,
whereas, except for spinal fusion surgery, most clinical applications
for bone regeneration tend to be for repair of defects where the
availability or supply of bone precursor cells may be less than in
just below the periosteum. The defect models have a larger
negative impact on the animals’ well-being. In contrast to the
defect models in the rat, the model presented here is much faster
and easier to perform, and it is certainly more clinically relevant
than the ectopic bone model, since the formation of bone occurs in
an orthotopic site. In addition, since it is based on a single injection
Rat Subperiosteal Cranial Model
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at a specific site, this model is nearly non-invasive and highly
reproducible (low standard deviation in the groups) that can lead
to a reduction in the number of animals during the course of the
study. Consequently, this model is in accord with the principles of
the 3 Rs (refinement, reduction, replacement) [43] and, at the
same time, allows the possibility of conducting large initial
screenings of bone-inducing constructs. Moreover, since HA gels
and BMP-2 has been already used in the patients [44,45], we
considered future clinical translation of the construct presented in
the study. However, we must be aware that the complexity of
human body requires that the final judgment of certain therapy
utility and its specific application can be made only after a clinical
trial with a long follow-up.
Materials and Methods
1. Protocol
The surgical protocol was approved by the Local Animal
Committee of Uppsala University, Sweden (approval no. 222/10).
Housing and experiments were performed accordingly to the
European Community Council Directive (86/609/EEC). Twelve
adult male Sprague-Dawley rats (Taconic M&B, Lille Skensved,
Denmark) weighting approximately 250–300 g were housed in a
specialized animal facility with an adjusted conditions such as
temperature 22–24uC, relative humidity 30–60% and light/dark
hours schedule: 12/12. The rats were maintained two per cage
and with ad libitum access to water and standard rodent diet.
Individual body weight was recorded prior to intervention.
Animals were acclimated for 10 days prior to surgery. Special
attention was given to perform each procedure with the same
order and time interval.
2. Injectable Construct
Recombinant human BMP-2 (InductOsH Pfizer, former Wyeth
Europe) delivered as a lyophilized powder in a formulation buffer
containing 2.5% glycine, 0.5% sucrose, 0.01% Polysorbate 80,
5 mM NaCL and 5 mM L-glutamic acid, was reconstituted at
concentration of 1.5 mg/mL according to the manufacturer’s
instructions by the addition of deionized water and stored at 4uC.
The lyophilized form of hydrogel components were synthesised as
described elsewhere [12]. Briefly, HA aldehyde (HA-al) and HA
hydrazyde (HA-hy) derivatives were dissolved at 16 mg/mL in
PBS. HA-hy mixed or not with BMP-2 was loaded into a one
1 mL sterile Luer-lock syringe (Bectron Dickens Medical) and
connected by a Luer-lock adapter (Qosina) to another 1 mL
syringe loaded with HA-al. The final concentration of BMP-2 was
150 mg or 5 mg per 1 mL of gel. The solutions were mixed 30
times back and forward for 30 s at a room temperature. The
gelation time was approximately 1 min.
3. In vivo Experiment
3.1 Experimental design. Rats were randomly placed in
four groups (n = 3) that were treated with 200 mL of the following
constructs: (i) HA gel with 30 mg of BMP-2 (ii) HA gel with 1 mg of
BMP (iii) gel without BMP-2 and (iv) saline. After 6 weeks, animals
were sacrificed by CO2 asphyxiation. The area of injection with
1 cm of neighboring bone was collected from the skull. The
samples were fixed in 4% paraformaldehyde in PBS at pH 7.4 for
at least 48 h at room temperature and stored in 70% ethanol until
further analysis.
3.2 Surgical procedure. All surgical procedures were carried
out under strictly aseptic and antiseptic conditions. Rats were
anesthetized with isoflurane (ForeneH, Abbott Scandinavia). After
an induction with 5% isoflurane in a small induction chamber,
animals were placed in a prone position and anesthesia was
maintained with 2% isoflurane in oxygen delivered via a facemask.
Once sedated, the rats were shaved and the cranial surface was
disinfected with iodine solution and alcohol. The periosteum of
frontal bone was exposed by a midline skin incision of
approximately 1 cm long, using a surgical blade. A blunt needle
(21G) attached to one 1 mL syringe was inserted under the bone
periosteum at 45u to the frontal bone surface. The needle was
shifted for 15 mm towards the face direction. The periosteum was
carefully elevated by the tip in left and right directions. A volume
of 200 mL injectable construct or ,40 mL saline was placed into
the subperiosteal space. This amount of saline was used in the
previous study where the solution was placed in the periosteal
space of the mandibular bone in the rat [6]. In order to avoid the
risk of the periosteal contraction we used the same dose of saline.
Then, the wound was carefully closed by suturing the skin (4-0
suture, EthilonTM, Ethicon) and there was no need for suturing the
periosteum. The intervention was shown in a video file (Video S1).
Postoperative pain was managed by the administration of
0.05 mg/kg buprenorphine (Temgesic, Schering-Plough) subcu-
taneously. Animals presented no sign of pain, distress or infection.
Rats were allowed to move freely and were monitored daily.
4. Bone Evaluation
4.1 Bone volume calculation. Following sacrifice, the
clavariae were resected using an oscillating autopsy saw. Micro-
CT analyses were performed using the Skyscan 1072 micro-CT
imaging system (Skyscan, Kontich, Belgium) after placing the
samples vertically onto the sample holder. Micro-CT images were
acquired with a spatial resolution of 18.88 mm (X-ray Source
100 kV/98 kA; Ex posure Time 3.9 sec; Magnification 15X;
1 mm filter applied). Then, using NRecon V1.4 (SkyScan), a cone
beam reconstruction was performed on the projected files. Finally,
3D-reconstructions of the samples were obtained (3D-DOCTOR
4.0, Able Software Corp, Lexington, MA). Analysis was performed
in the same manner for each rat with a volume of interest
corresponding to the injection area. Average bone volume was
calculated as bone volume/total tissue volume (BV/TV, mm3). In
order to determine correlation between BV/TV and the dose of
BMP-2, we performed non-parametric Spearman correlation
coefficient. Furthermore, the following structural parameters were
estimated: trabecular number (TbN,/mm2), trabecular thickness
(TbTh, mm), trabecular separation (TbS, mm) and porosity (P, %).
The parameters TbN, TbTh, TbS and P were tested for normality
by the Shapiro-Wilks test. As the data were compatible with a
normal distribution, the two-tailed Student’s t-test for paired
samples was used in the comparison between groups [46]. The
standard deviation (SD) was calculated for n= 3. The differences
at P,0.05 was considered as statistically significant. The software
SAS version 8.2 was used.
4.2 Bone morphology observation. After micro-CT anal-
ysis, the cranial bone specimen was completely decalcified using an
electrophoresis system (Tissue-Tek Miles scientific, Histolab,
Go¨teborg) with formic acid. Following paraffin processing, 5 mm
thick cross-sections were cut with microtome (Thermo Microm
HM 355) and stained. For morphological evaluation, the cross
sections were stained with Hematoxylin and Eosin (H&E,
Histolab, Go¨teborg). Sections were photographed with a digital
camera connected to an optical microscope (Eclipse TE 2000U,
Nikon). For collagen observation, the sections were stained with
Sirius red (Fluka) [47] and photographed on the polarized light
microscope (Leica DM2500 P).
4.3 Expression of angiogenic and osteogenic markers in
bone. Immunofluorescence stainings were performed on paraf-
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fin sections to visualize osteocalcin (clone FL-100, Santa Cruz
Biotechnology) and CD31 (Abcam, ab28364). The sections were
deparaffinized, dehydrated in increasing ethanol solutions (ethanol
100-96-80-70-50%, 2 min each), washed in PBS (365 min),
incubated in a Target Antigen Retrieval Solution pH 9 (Dako)
at 95uC for 20 min, and washed with PBS. After blocking in 12%
bovine serum albumin (BSA) solution for 1 h at room tempera-
ture, the slides were incubated with primary antibody (anti-OC
antibody diluted 1:50, and anti-CD31 antibody diluted 1:50)
overnight at 4uC. Sections were then washed 3 times with PBS and
blocked for additional 15 min with 12% BSA in PBS. To visualize
the primary antibody, TRITC or FITC-conjugated polyclonal
swine or goat F(ab9)2 fragments directed to rabbit immunoglob-
ulins (Dako) were added to the sections. Slides were washed 3
times for 5 min in PBS. Sections not treated with the primary
antibody were used as a negative control. Finally, the slides were
incubated for 5 min in PBS containing 1 mg/mL of Hoechst
33342 (Sigma-Aldrich), washed again with PBS, and mounted
with Dako mounting solution (Dako). Pictures of immunofluores-
cence staining were taken with a DXM1200F digital camera
connected to a Nikon Eclipse TE2000-U inverted microscope.
The device was equipped with Hoechst 33342, FITC, and TRITC
filter sets (Nikon AG; Software: Nikon ACT-1 vers. 2.70). Images
were processed with Photoshop 7.0 (Adobe Systems Inc). Instead
of qualitative analysis, the density of blood vessels (number of
blood vessels per 10x field) was calculated. The standard deviation
(SD) was calculated from n= 3 (3 sections per sample). Compar-
isons between gel groups and the control group were made by the
two tailed Student’s t-test for paired samples (*p,0.05).
Conclusions
The evaluation of tissue engineering concepts for bone takes a
long time and requires relevant animal models that are suitable for
large screening. There is currently no orthotopic model in
common use that is cost-effective, easy to perform, reproducible,
and employs small animals. As a solution, we presented here a
minimally invasive subperiosteal rat model that can be a suitable
and relevant tool for the initial screening of regenerative medicine
strategies. The model offers a promising approach, even for
investigators with little experience in surgery. We have demon-
strated that this model provides a stable measuring tool for
assessing the biocompatibility and bioactivity of a tissue engineer-
ing construct. The outcomes can be rapidly assessed, by
correlating quantitative micro-CT data with histological analysis.
We believe that this new technique can be used as an alternative to
the defect models and can serve as a powerful tool for evaluating
regenerative medicine strategies and their mechanisms of action.
Supporting Information
Video S1 The video presents a new subperiosteal model
in the cranial bone of the rat. First, the anesthetized animal is
placed in a prone position. Further, anesthesia is maintained with
2% isoflurane in oxygen delivered via a facemask. The cranial
surface is shaved and disinfected. A surgical blade is used to expose
the periosteum of frontal bone by a midline skin incision of
approximately 1 cm long. Next, a blunt needle (21G) attached to
one 1 mL syringe is inserted under the bone periosteum at 45u to
the frontal bone surface. The needle is shifted for 15 mm towards
the face direction. The periosteum is carefully elevated by the tip
in left and right directions. Then, a volume of 200 mL injectable
construct is placed into the subperiosteal space. Finally, the wound
is closed by suturing the skin (4-0 suture, EthilonTM, Ethicon).
(ZIP)
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